KPTI
Price:
$0.7302
Market Cap:
$91.04M
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or ...[Read more]
Industry
Biotechnology
IPO Date
2013-11-06
Stock Exchange
NASDAQ
Ticker
KPTI
According to Karyopharm Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is 66.89%. This represents a change of 286.66% compared to the average of 17.30% of the last 4 quarters.
The mean historical ROE of Karyopharm Therapeutics Inc. over the last ten years is 10.31%. The current 66.89% ROE has changed 548.76% with respect to the historical average. Over the past ten years (40 quarters), KPTI's ROE was at its highest in in the December 2022 quarter at 231.18%. The ROE was at its lowest in in the December 2019 quarter at -97.74%.
Average
10.31%
Median
-63.56%
Minimum
-400.99%
Maximum
992.38%
Discovering the peaks and valleys of Karyopharm Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 537.18%
Maximum Annual ROE = 992.38%
Minimum Annual Increase = -140.11%
Minimum Annual ROE = -400.99%
Year | ROE | Change |
---|---|---|
2023 | 105.06% | -89.41% |
2022 | 992.38% | 537.18% |
2021 | 155.75% | -140.11% |
2020 | -388.31% | -3.16% |
2019 | -400.99% | 311.70% |
2018 | -97.40% | -2.24% |
2017 | -99.63% | 47.51% |
2016 | -67.54% | 13.36% |
2015 | -59.58% | 62.59% |
2014 | -36.64% | 67.24% |
The current ROE of Karyopharm Therapeutics Inc. (KPTI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
417.73%
5-year avg
92.78%
10-year avg
10.31%
Karyopharm Therapeutics Inc.’s ROE is less than X4 Pharmaceuticals, Inc. (32.93%), greater than HOOKIPA Pharma Inc. (-51.77%), greater than Mereo BioPharma Group plc (-63.39%), less than Galera Therapeutics, Inc. (21.95%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Nuvation Bio Inc. (-98.79%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Kronos Bio, Inc. (-68.82%), greater than Gossamer Bio, Inc. (-117.33%), greater than Agios Pharmaceuticals, Inc. (-47.05%), greater than bluebird bio, Inc. (-38.30%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), less than PMV Pharmaceuticals, Inc. (0%), greater than Rallybio Corporation (-21.96%), greater than Generation Bio Co. (-74.08%), greater than Mersana Therapeutics, Inc. (-92.86%), greater than Monte Rosa Therapeutics, Inc. (-333.91%), greater than null (-70.40%),
Company | ROE | Market cap |
---|---|---|
32.93% | $109.78M | |
-51.77% | $159.50M | |
-63.39% | $664.26M | |
21.95% | $4.08M | |
-24.63% | $133.38M | |
-27.44% | $93.74M | |
-98.79% | $692.60M | |
-47.64% | $8.20M | |
-121.55% | $107.81M | |
-143.74% | $17.85M | |
-52.15% | $708.49M | |
-152.26% | $115.27M | |
-68.82% | $59.36M | |
-117.33% | $205.87M | |
-47.05% | $2.46B | |
-38.30% | $101.94M | |
-78.24% | $794.69M | |
0% | $77.28M | |
-21.96% | $45.64M | |
-74.08% | $145.50M | |
-92.86% | $165.61M | |
-333.91% | $349.21M | |
-70.40% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Karyopharm Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Karyopharm Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Karyopharm Therapeutics Inc.'s ROE?
How is the ROE calculated for Karyopharm Therapeutics Inc. (KPTI)?
What is the highest ROE for Karyopharm Therapeutics Inc. (KPTI)?
What is the 3-year average ROE for Karyopharm Therapeutics Inc. (KPTI)?
What is the 5-year average ROE for Karyopharm Therapeutics Inc. (KPTI)?
How does the current ROE for Karyopharm Therapeutics Inc. (KPTI) compare to its historical average?